NNIT NNIT A/S

NNIT A/S: 10/2020 Financial report for the first six months of 2020

NNIT A/S: 10/2020 Financial report for the first six months of 2020

Company announcement 10/2020: Financial report for the first six months of 2020

Revenue decrease of 4.7% and an operating profit margin before special items of 6.0% in the first six months of 2020

Performance highlights for the second quarter of 2020:

  • Revenue decreased by 5.7% in Q2 2020 compared to Q2 2019 due to a 26% decline from the Novo Nordisk Group and a 10% decline within the enterprise segment
  • Revenue from life sciences Denmark and life sciences international increased by 22% and 18% respectively whilst the public segment contributed with a strong growth of 12%. Revenue within the finance segment declined by 3.4% whilst revenue from the enterprise segment declined by 10% mainly due to the phasing out of the Pandora outsourcing contract
  • By the end of Q2 2020, the share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 75% from 68% in Q2 2019
  • COVID-19 was seen to mainly impact NNIT’s project business in April and May whilst growth returned to more normal levels in June
  • Gross profit margin was 13% in Q2 2020 (13% in Q2 2019). The margin was negatively impacted by the declining business with the Novo Nordisk Group and Pandora and as a result of COVID-19. The negative impact was partly offset by the cost restructuring program. An asset review of the useful lifetime of certain assets had a positive margin impact of 1.0pp for the quarter (+0.4pp for the full year)
  • Operating profit margin before special items decreased to 5.4% in Q2 2020 from 5.9% in Q2 2019. Operating profit margin after special items for the quarter was 3.6%
  • Net profit was DKK 14m in Q2 2020 compared to DKK 34m in Q2 2019 due to restructuring costs of DKK 13m as well as a negative impact from financials
  • Order backlog for 2020 at the beginning of Q3 2020 was DKK 2.507m, a decrease of 8.1% compared to the same time last year, negatively impacted by a large decline of 29% from the Novo Nordisk Group
  • Outlook for 2020:

The guidance for 2020 is maintained:

  • Revenue growth of -4% to -8% in constant currencies
  • Operating profit margin before special items of 6-8% in constant currencies
  • Level of investments (CAPEX) is 5-7% of total revenue

Due to the continued uncertainty regarding the COVID-19 impact on the 2020 activity level there is an increased likelihood that revenue growth and operating profit margin will end in the lower end of the guidance intervals

  • Due to the underlying cash flow generation and the strong financial position of NNIT, the Board of Directors has decided to pay an interim dividend for 2020 of DKK 2.00 per share corresponding to DKK 49.4 million

Per Kogut, CEO at NNIT comments: “I’m satisfied with the financial performance of the quarter which is in line with our expectations despite COVID-19 and declining revenue from the Novo Nordisk Group and Pandora. This is achieved by solid revenue growth within our life science business growing 20%, as well as execution of the cost restructuring program.”

Conference call details

NNIT will host a teleconference August 13, 2020 at 10:30 CET about the financial report for the first six months of 2020. Please visit the NNIT webpage at to access the teleconference, which can be found under ‘Investors – Events & presentations. Presentation material will be available on the website approximately one hour prior to the start of the presentation.

Conference call details

Participant telephone numbers:

Denmark:                                    0

United Kingdom:                        9

Sweden:                                     

United States:                           

Financial Calendar 2020

August 17, 2020                        Interim dividend ex-dividend date

August 18, 2020                        Interim dividend record day

August 19, 2020                        Interim dividend payment date

October 29, 2020                      Interim report for the first nine months of 2020

Forward-looking statements

This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.

Please also refer to the overview of risk factors in the ‘risk management’ section on page 29-31 in the Annual Report 2019.

Contacts for further information

Investor relations:                              Media relations:                

Jens Binger                                          Tina Joanne Hindsbo

Head of Investor Relations          NNIT Communications                 

Tel:                           Tel:                          

                                                                                                  

 

About NNIT

NNIT A/S is one of Denmark’s leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of June 30, 2020, NNIT A/S had 3,078 employees. NNIT has approximately 400 clients of which around 150 are located outside Denmark. Some 25% are international life sciences clients. For more information please visit .

Attachment

EN
13/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NNIT A/S

 PRESS RELEASE

NNIT A/S: NNIT shares its financial calendar for 2026

NNIT A/S: NNIT shares its financial calendar for 2026 The financial calendar for 2026: 28 January 2026Deadline for shareholder proposals for the Annual General Meeting5 February 2026Interim Financial Report Q4 2025 and Annual Report 202512 March 2026Annual General Meeting12 May 2026Interim Financial Report Q1 202627 August 2026Interim Financial Report H1 20265 November 2026Interim Financial Report Q3 2026 For more information, please contact: Investor RelationsCarsten RingiusEVP & CFOTel: Media RelationsThomas StensbølPress & Communications ManagerTel: ABOUT NNIT NNIT is a leadi...

ABGSC IT Research ... (+2)
  • ABGSC IT Research
  • Mikkel Kousgaard Rasmussen
ABGSC IT Research ... (+2)
  • ABGSC IT Research
  • Mikkel Kousgaard Rasmussen
 PRESS RELEASE

NNIT A/S: On-track performance with doubled profitability

NNIT A/S: On-track performance with doubled profitability Q3 2025 key highlights While business was still being negatively impacted by macroeconomic and geopolitical uncertainty, there was an uplift in financial performance in the third quarter. Group operating profit excluding special items more than doubled at DKK 35.6m, corresponding to a margin of 8.2% against 3.9% in the third quarter of 2024. The step-change in margin development compared with last quarter and last year was driven by more efficient operations in terms of improving utilization and the effect from cost reducing initiat...

 PRESS RELEASE

NNIT A/S: NNIT restates its life science segment in its financial repo...

NNIT A/S: NNIT restates its life science segment in its financial reporting structure Today, NNIT announces an update to its financial reporting structure to ensure that all Life Sciences customers are fully consolidated under Region Europe, US, and Asia. As a result, all Life Science customers previously reported under Region Denmark irrespective of the business activity will now be included in Region Europe’s profit and loss statement. Going forward, Region Denmark will consist solely of the Public segment and the Private segment, which includes SCALES. The restatement of the Life Scienc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch